Navigation Links
Isis Pharmaceuticals to Present at Goldman Sachs' 30th Annual Global Healthcare Conference
Date:6/4/2009

CARLSBAD, Calif., June 4 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Goldman Sachs 30th Annual Global Healthcare Conference on Wednesday, June 10, 2009, at 4:30 p.m. ET at the Grand Hyatt Hotel in New York City.

A live audio webcast of the presentation will be available on the "Investor Center" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... ... prominently feature 150+ Hospital and Health System Executive Speakers including: , , ... President of the United States of America: George W. Bush , Boxing Legend, ... Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh , ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... help improve all aspects of people’s health and nutrition, announced its product Leyzene ... , Natural Subsistence develops nutritional supplements that help people improve all aspects ...
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of Quality Assurance and Utilization ... ABQAURP’s dedication to Health Care Quality and Management and Patient Safety. , It is ... the association, but also to the Health Care Quality and Patient Safety movements. Diplomates ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 — ... the new EU MDR language change the way manufacturers approach CERs? , ...
(Date:3/23/2017)... ... March 23, 2017 , ... “Beyond and Back”: a true-life ... is the creation of published author Bonetta Rose, a wife, mother and grandmother committed ... Published by Christian Faith Publishing, Bonetta Rose‘s new book presents actual events in the ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... ReNeuron reported in December 2016 positive Phase II trial ... not meeting the three-month time frame of a two-point improvement ... (ARAT). As a result, the company has confirmed that it ... Beyond CTX, we expect safety and efficacy data from its ... from its critical limb ischaemia (CLI) trial. Our rNPV has ...
(Date:3/23/2017)... , Mar 23, 2017 The Board ... to the Annual General Meeting, which is to take place on ... 2 in Lund, Sweden . ... Please see the attached notification, which ... Inrikes Tidningar. NeuroVive Pharmaceutical AB (Publ) The Board Of ...
(Date:3/22/2017)... Corp. (NASDAQ: DRIO), a leading global digital health ... today reported financial and operational results for the ... 2016. 2016 Highlights ... to the full year 2015  ... Direct-to-consumer model launched in U.S. ...
Breaking Medicine Technology: